Grant of Options and PDMR notification

RNS Number : 4420P

Oncimmune Holdings PLC

09 June 2020

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Grant of Options and PDMR notification

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group , today announces t hat, as part of its annual management incentivisation scheme, options ("Options") to subscribe for an aggregate of 324,474 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted on 5 June 2020 to each of Adam Hill, Chief Executive Officer, Matthew Hall, Chief Financial Officer, Matthew Luttrell, Chief Commercial Officer, and Tariq Sethi, Chief Scientific Officer as follows:

Name	Position	Number of Share Options Awarded	Exercise Price per Ordinary Share	Total Options held post grant	Total number of Ordinary Shares currently held	% of total issued share capital
Adam Hill	Chief Executive Officer	129,288	£1.195	526,113	40,913	0.06%
Matthew Hall	Chief Financial Officer	134,936	£1.195	295,486	11,935	0.02%
Matthew Luttrell	Chief Commercial Officer	42,677	£1.195	266,361	-	-
Tariq Sethi	Chief Scientific Officer	17,573	£1.195	109,678	-	-

The Options have been granted under the 2016 Share Option Plan, have an exercise price of £1.195, being the closing price of Ordinary Shares on  4 June 2020, and vest annually in five equal parts from the date of grant until the fifth anniversary of grant.  

This announcement, including the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	1)  Adam Hill 2)  Matthew Hall 3)  Matthew Luttrell 4)  Tariq Sethi
2	Reason for the notification
a)	Position/status	1)  Chief Executive Officer 2)  Chief Financial Officer 3)  Chief Commercial Officer 4)  Chief Scientific Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oncimmune Holdings plc
b)	LEI	213800HCYIWT6YPI1I02
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	ISIN: GB00BYQ94H38
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1) £ 1.195	129,288
			2) £1.195	134,936
			3) £1.195	42,677
			4) £1.195	17,573
d)	Aggregated information
	- Aggregated volume	As above
	- Price
e)	Date of the transaction	5 June 2020
f)	Place of the transaction	Outside a trading venue

For further information:

Oncimmune Holdings plc

Ron Kirschner, General Counsel & Company Secretary

[e-mail]

 

END

 

 

DSHUPUGAQUPUGCB